2564-00-3

Basic information

• Product Name: N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE
• Synonyms: BUTTPARK 80\07-89;ASISCHEM P20608;2-CHLORO-N-(4-IODOPHENYL)ACETAMIDE;AKOS B028894;N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE;2-chloro-N-(4-iodophenyl)ethanamide;ST5411068;ZINC00152932
• CAS NO: 2564-00-3
• Molecular Formula: C₈H₇ClINO
• Molecular Weight: 295.5
• Mol File: 2564-00-3.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 402.3°C at 760 mmHg
• Flash Point: 197.1°C
• Appearance: White to light brown/Crystalline Powder
• Density: 1.894g/cm³
• Vapor Pressure: 1.11E-06mmHg at 25°C
• Refractive Index: 1.67
• CAS DataBase Reference: N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE(2564-00-3)
• EPA Substance Registry System: N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE(2564-00-3)

Safety Data

• Hazardous Substances Data: 2564-00-3(Hazardous Substances Data)

Usage

General Description

N1-(4-Iodophenyl)-2-chloroacetamide is a chemical compound with the molecular formula C8H7ClIN2O and a molecular weight of 293.51 g/mol. It is a derivative of acetamide with a chlorine atom and an iodine-substituted phenyl group attached to the nitrogen atom of the amide. N1-(4-IODOPHENYL)-2-CHLOROACETAMIDE has been studied for its potential use in pharmaceutical research, particularly in the development of new drugs with antimicrobial or anti-inflammatory properties. It may also have applications in organic synthesis and chemical reactions due to its unique structural features. The exact properties and uses of N1-(4-Iodophenyl)-2-chloroacetamide are still being explored and investigated by scientists and researchers.

InChI:InChI=1/C8H7ClINO/c9-5-8(12)11-7-3-1-6(10)2-4-7/h1-4H,5H2,(H,11,12)

Upstream product

• 107-14-2 chloroacetonitrile 
• 22118-09-8 2-bromoacetyl chloride 
• 540-37-4 p-aminoiodobenzene 
• 19103-78-7 chloroacetyl isothiocyanate 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 936633-08-8 2-(4-aminophenoxy)-N-(4-iodophenyl)acetamide 
• 936632-70-1 1-deoxy-1-(6-{4-[(4-iodophenylcarbamoyl)methoxy]phenylamino}-9H-purin-9-yl)-N-ethyl-2,3-O-(1-methylethylidene)-β-D-ribofuranuronamide 
• 270086-79-8 N-(4-iodo-phenyl)-2-pyrrolidin-1-yl-acetamide 
• 81112-63-2 N-(4-Iodo-phenyl)-2-piperidin-1-yl-acetamide; compound with oxalic acid 
• 88951-61-5 N-(4-Iodo-phenyl)-2-(4-{[(E)-4-nonyloxy-phenylimino]-methyl}-phenoxy)-acetamide 
• 88951-60-4 N-(4-Iodo-phenyl)-2-(4-{[(E)-4-octyloxy-phenylimino]-methyl}-phenoxy)-acetamide 
• 88951-59-1 2-(4-{[(E)-4-Heptyloxy-phenylimino]-methyl}-phenoxy)-N-(4-iodo-phenyl)-acetamide 
• 88951-58-0 2-(4-{[(E)-4-Hexyloxy-phenylimino]-methyl}-phenoxy)-N-(4-iodo-phenyl)-acetamide 
• 88951-57-9 N-(4-Iodo-phenyl)-2-(4-{[(E)-4-pentyloxy-phenylimino]-methyl}-phenoxy)-acetamide 
• 88951-56-8 2-(4-{[(E)-4-Butoxy-phenylimino]-methyl}-phenoxy)-N-(4-iodo-phenyl)-acetamide 
• 88951-55-7 N-(4-Iodo-phenyl)-2-(4-{[(E)-4-propoxy-phenylimino]-methyl}-phenoxy)-acetamide 
• 88951-54-6 2-(4-{[(E)-4-Ethoxy-phenylimino]-methyl}-phenoxy)-N-(4-iodo-phenyl)-acetamide 
• 88951-53-5 N-(4-Iodo-phenyl)-2-(4-{[(E)-4-methoxy-phenylimino]-methyl}-phenoxy)-acetamide 
• 88951-52-4 2-(4-{[(E)-4-Hydroxy-phenylimino]-methyl}-phenoxy)-N-(4-iodo-phenyl)-acetamide 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 5-(4-chlorophenyl)-4-phenyl-4H-1,2,4-triazole-3-thiols as an anticancer agent

Cellular tumor antigen p53 is significant for cancer prevention and its mutation is most documented genomic change in human cancers. Thus, restoration of p53 function by interruption of the p53-MDM2 interaction opens up a prospect for a nongenotoxic anticancer therapeutic strategy. A novel series of molecules comprising 1,2,4-triazole-3-thiol scaffold were successfully discovered by structure-based designing approach. In silico modules predicted that 5-(4-chlorophenyl)-4-phenyl-4H-1,2,4-triazole-3-thiol derivatives have draggability and ability to mimic critical binding residues of p53. All target compounds were assayed for their in vitro antiproliferative activity against A549, U87 and HL60 cell lines. Twelve out of sixteen compounds exhibited good in vitro inhibitory activity in micromolar range. Especially, compound 6h possessed acute antitumor activity with IC50 values 3.854, 4.151 and 17.522 μM against three tested cell lines. It represents as a promising lead for further optimization and a template for development of novel antitumor agents.

Novel 1,3,4-oxadiazole compounds inhibit the tyrosinase and melanin level: Synthesis, in-vitro, and in-silico studies

In this research work, we have designed and synthesized some biologically useful of 1,3,4-Oxadiazoles. The structural interpretation of the synthesized compounds has been validated by using FT-IR, LC-MS, HRMS, 1H NMR and 13C NMR techniques. Moreover, the in-vitro mushroom tyrosinase inhibitory potential of the target compounds was assessed. The in-vitro study reveals that, all compounds demonstrate an excellent tyrosinase inhibitory activity. Especially, 2-(5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-ylthio)-N-phenylacetamide (IC50 = 0.003 ± 0.00 μM) confirms much more significant potent inhibition activity compared with standard drug kojic acid (IC50 = 16.83 ± 1.16 μM). Subsequently, the most potent five oxadiazole compounds were screened for cytotoxicity study against B16F10 melanoma cells using an MTT assay method. The survival rate for the most potent compound was more pleasant than other compounds. Furthermore, the western blot results proved that the most potent compound considerably decreased the expression level of tyrosinase at 50 μM (P 0.05). The molecular docking investigation exposed that the utmost potent compound displayed the significant interactions pattern within the active region of the tyrosinase enzyme and which might be responsible for the decent inhibitory activity towards the enzyme. A molecular dynamic simulation experiment was presented to recognize the residual backbone stability of protein structure.

Synthesis of Arylamides via Ritter-Type Cleavage of Solid-Supported Aryltriazenes

A novel route for the synthesis of N-arylamides via the cleavage of aryltriazenes with alkyl or aryl nitriles is presented. We developed a variation of the Ritter reaction that allows the use of acetonitrile as solvent and reagent in reactions with solid-supported precursors. The reaction was optimized for the generation of N-aryl acetamides using a diverse range of immobilized building blocks including o-, m-, and p-substituted aryltriazenes. The cleavage via the Ritter-type conversion was combined with an on-bead cross-coupling reaction of halogen-substituted aryltriazenes with pyrazoles. Additionally, the synthesis of on-bead generated arylboronic ester-substituted triazenes was shown. The developed procedure was further expanded to use other commercially available nitriles, such as acrylonitrile, benzonitrile, and chlorinated alkyl nitriles as suitable reagents for a Ritter-type cleavage of the prepared triazene linkers.